There is a good reason for the non-performance. I think you have been here long enough to remember the failure in HCV-796; a drug if VPHM can push along with ex-Wyeth into PIII would have seen this stock trading in the 40s by now. Secondly, the unspeakable debacle in PIII of Maribavir for Stem Cell Transplantation as a prohylaxsis against cytomegalovirus. If it wasn't for the pristine balance generated by Oral Vancocin and more importantly the acquisition of Cinryze from Lev Pharma; we may very well looking at a stock trading below 4. That said, it's still great to take advantage of the ups and downs as presented by Market condition. On another note, anyone notices during the call which Analysts are missing from the coverage???. I am afraid we lost our most vehement ally Mr.Thomas Wei.